Aardvark Therapeutics, Inc. Common Stock beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging +0.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.87 | $-0.66 | +24.1% | Beat | |
| Q1 FY26 | $-0.81 | $-0.99 | -22.2% | Miss | |
| Q4 FY25 | $-0.81 | $-0.81 | +0.0% | Beat |
Back to AARD overview · AARD holders · AARD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.